BR0212676A - compostos terapêuticos ligantes de 5-ht, composições farmacêuticas compreendendo tais compostos e seus usos - Google Patents

compostos terapêuticos ligantes de 5-ht, composições farmacêuticas compreendendo tais compostos e seus usos

Info

Publication number
BR0212676A
BR0212676A BRPI0212676-1A BR0212676A BR0212676A BR 0212676 A BR0212676 A BR 0212676A BR 0212676 A BR0212676 A BR 0212676A BR 0212676 A BR0212676 A BR 0212676A
Authority
BR
Brazil
Prior art keywords
compounds
pharmaceutical compositions
ligand therapeutic
formula
therapeutic compounds
Prior art date
Application number
BRPI0212676-1A
Other languages
English (en)
Inventor
Jian-Min Fu
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR0212676A publication Critical patent/BR0212676A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"COMPOSTOS TERAPêUTICOS LIGANTES DE 5-HT, COMPOSIçõES FARMACêUTICAS COMPREENDENDO TAIS COMPOSTOS E SEUS USOS". A presente invenção fornece compostos de Fórmula (I): em que: R¬ 1¬, R¬ 2¬, R¬ 3¬, R¬ 4¬, R¬ 5¬, R¬ 6¬, R¬ 7¬, R¬ 8¬, n, m e X têm qualquer dos valores definidos na especificação, assim como composições farmacêuticas que compreendem os compostos. A invenção também fornece métodos terapêuticos assim como processos e intermediários úteis para preparar compostos de Fórmula (I). Os compostos são ligantes de 5-HT e são úteis para tratar doenças em que se deseja modulação de atividade de 5-HT.
BRPI0212676-1A 2001-09-21 2002-09-19 compostos terapêuticos ligantes de 5-ht, composições farmacêuticas compreendendo tais compostos e seus usos BR0212676A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32366601P 2001-09-21 2001-09-21
PCT/US2002/030089 WO2003024976A2 (en) 2001-09-21 2002-09-19 Tricyclic indole derivatives as 5-ht ligands

Publications (1)

Publication Number Publication Date
BR0212676A true BR0212676A (pt) 2006-05-23

Family

ID=23260193

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0212676-1A BR0212676A (pt) 2001-09-21 2002-09-19 compostos terapêuticos ligantes de 5-ht, composições farmacêuticas compreendendo tais compostos e seus usos

Country Status (8)

Country Link
US (1) US6887868B2 (pt)
EP (1) EP1429776A2 (pt)
JP (1) JP2005527477A (pt)
AU (1) AU2002336749A1 (pt)
BR (1) BR0212676A (pt)
CA (1) CA2460126A1 (pt)
MX (1) MXPA04002615A (pt)
WO (1) WO2003024976A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
AR059356A1 (es) * 2006-02-14 2008-03-26 Astrazeneca Ab Nuevos radioligandos
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
US9216998B2 (en) * 2012-02-15 2015-12-22 Janssen Pharmaceutica Nv Tricyclic indole derivatives useful endothelial lipase inhibitors
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
NZ227229A (en) * 1987-12-10 1991-03-26 Duphar Int Res Indole derivatives and pharmaceutical compositions
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
ZA902794B (en) 1989-04-18 1991-04-24 Duphar Int Res New 3-n substituted carbamoyl-indole derivatives
GB8913646D0 (en) 1989-06-14 1989-08-02 Glaxo Group Ltd Chemical compounds
HUT61548A (en) 1990-08-27 1993-01-28 Sandoz Ag Process for producing indolonaphthyridine derivatives and pharmaceutical compositions comprising such compounds
ID27510A (id) * 1998-07-30 2001-04-12 Japan Tobacco Inc Senyawa malimida tersubstitusi dan penggunaan farmasinya
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
ATE277048T1 (de) * 1999-06-15 2004-10-15 Bristol Myers Squibb Pharma Co Substituierte hetercyclisch kondensierte gamma carboline

Also Published As

Publication number Publication date
JP2005527477A (ja) 2005-09-15
MXPA04002615A (es) 2004-07-08
WO2003024976A2 (en) 2003-03-27
US20030087883A1 (en) 2003-05-08
US6887868B2 (en) 2005-05-03
CA2460126A1 (en) 2003-03-27
WO2003024976A3 (en) 2004-02-12
AU2002336749A1 (en) 2003-04-01
EP1429776A2 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
BR0211559A (pt) Compostos, composições de ligantes tetracìclicos terapeuticamente úteis e seus usos
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
BR0212676A (pt) compostos terapêuticos ligantes de 5-ht, composições farmacêuticas compreendendo tais compostos e seus usos
BR0210358A (pt) Inibidores da protease de hiv, composições contendo os mesmos, seus usos farmacêuticos e materiais para sua sìntese
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
BRPI0417571A (pt) 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-ciclohexil-alquila substituìda como inibidores da poli(adp-ribose) polimerase
BRPI0416004A (pt) composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo
WO2006034833A1 (en) Cyclic diarly ureas suitable as tyrosine kinase inhibitors
BR0213417A (pt) Compostos e composições de tetraciclicazaindóis e indolinas tendo atividade de 5-ht e seus usos
BRPI0414544A (pt) 2,4-di-(fenilamino) pirimidinas úteis no tratamento de transtornos proliferativos
BR0307631A (pt) Piridinonas substituìdas como moduladores de p38 map-quinase
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
MX2010010151A (es) Moduladores de cinasa aurora y metodo de uso.
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
BRPI0416532A (pt) 2-quinolinonas e 2-quinoxalinonas substituìdas por 6 como inibidores da poli(adp-ribose) polimerase
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BR0317459A (pt) Novos derivados de piperidina como moduladores do receptor ccr5 quimiocina
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
SE0103818D0 (sv) Chemical compounds
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
BR0316108A (pt) Derivados de fenilalquil e piridilalquil piperazina e composição farmacêutica compreendendo os mesmos
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
BR0315995A (pt) Composto, uso de um composto composição farmacêutica, métodos para a terapia da dor, de distúrbios gastrointestinais, e da ansiedade em um animal de sangue quente, e, processo para preparar um composto

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.